Enclomiphene Citrate vs Testosterone Enanthate: Switching Between Them

How Each Drug Works: Two Opposite Strategies for Raising Testosterone

Enclomiphene citrate and testosterone enanthate both treat male hypogonadism. They do it through completely different mechanisms.

Enclomiphene is the trans-isomer of clomiphene citrate, a SERM that blocks estrogen receptors at the hypothalamus and pituitary. By removing estrogen's negative feedback signal, enclomiphene triggers increased secretion of gonadotropin-releasing hormone (GnRH), which drives LH and FSH release. The result: the testes produce more testosterone endogenously. Kim et al. demonstrated in a study of men with secondary hypogonadism that enclomiphene restored serum testosterone to eugonadal levels while preserving spermatogenesis 1. LH and FSH stayed elevated or increased throughout the treatment period.

Testosterone enanthate works by the opposite principle. It supplies exogenous testosterone directly into circulation via intramuscular or subcutaneous injection. The hypothalamus detects supraphysiological androgen levels and shuts down GnRH pulsatility. LH and FSH fall to near-undetectable concentrations. The T-Trials, a coordinated set of seven double-blind, placebo-controlled studies in 790 men aged 65 and older with low testosterone, showed that testosterone gel (a close pharmacological cousin of enanthate) improved sexual function, physical function, and vitality scores over 12 months [2]. Testicular volume decreases on exogenous testosterone, and sperm counts drop below 1 million/mL in roughly 65% of men within 6 months according to data published in the Journal of Clinical Endocrinology & Metabolism.

This mechanistic split is the entire reason switching protocols matter.

When Switching Makes Clinical Sense

The decision to switch between enclomiphene and testosterone enanthate usually comes down to three scenarios: fertility planning, symptom adequacy, or cost and access changes.

A man on testosterone enanthate who decides he wants to conceive needs to restore spermatogenesis. Exogenous testosterone acts as a male contraceptive. The American Urological Association guidelines on male infertility specifically warn against testosterone therapy in men seeking fertility. Switching to enclomiphene allows testosterone levels to remain supported while the HPG axis recovers gonadotropin output and testicular function resumes sperm production.

The reverse scenario is also common. A man on enclomiphene who has achieved his family-building goals but finds that his total testosterone plateaus at 450 ng/dL (below his symptomatic relief threshold) may benefit from switching to testosterone enanthate, which can reliably target trough levels of 550-700 ng/dL with dose titration. Some men also experience SERM-related side effects (visual disturbances, mood changes, elevated estradiol relative to testosterone) that make long-term enclomiphene use less tolerable 3.

Insurance coverage and drug access can also force a switch. Enclomiphene citrate does not have full FDA approval for hypogonadism (as of mid-2026), and compounding pharmacy sourcing introduces variability in cost and availability.

Switching from Enclomiphene to Testosterone Enanthate

This direction is pharmacologically simple. Here is why.

Enclomiphene does not suppress the HPG axis. When you stop it, LH and FSH remain at physiological or slightly elevated levels for several days before drifting back to baseline. There is no "crash" in the way that stopping exogenous testosterone causes one. A clinician can initiate testosterone enanthate at a standard starting dose of 100-150 mg per week immediately after the last enclomiphene dose, or within 5-7 days of discontinuation.

The recommended protocol:

1. Draw baseline labs on the current enclomiphene regimen: total testosterone, free testosterone, LH, FSH, estradiol, SHBG, CBC, and PSA.
2. Discontinue enclomiphene.
3. Begin testosterone enanthate injections at the prescribed dose.
4. Recheck labs at 6-8 weeks (timing based on reaching steady-state, since testosterone enanthate's terminal half-life is approximately 4.5 days and steady-state requires roughly 4-5 half-lives).
5. Adjust dose based on trough total testosterone (target 550-900 ng/dL per the Endocrine Society 2018 guidelines), hematocrit (keep below 54%), and estradiol.

If the man was using enclomiphene specifically for fertility preservation and has now completed family building, confirm a semen analysis and reproductive counseling have occurred before initiating testosterone enanthate. Once on exogenous testosterone, sperm suppression typically begins within 2-3 months and can take 6-12 months or longer to recover if the drug is later discontinued 4.

Switching from Testosterone Enanthate to Enclomiphene

This is the harder direction. The HPG axis has been suppressed, and recovery takes time.

When exogenous testosterone is withdrawn, the hypothalamus and pituitary must resume GnRH pulsatility and gonadotropin secretion. In younger men (under 40), this recovery typically begins within 2-4 weeks and may normalize within 2-3 months. In older men or those on long-term TRT (more than 2 years), recovery can take 3-6 months, and some men experience incomplete recovery of LH and FSH 5.

The standard approach involves a washout-and-bridge strategy:

Step 1: Discontinue testosterone enanthate. The drug clears to sub-therapeutic levels within 2-3 weeks given its 4.5-day half-life.

Step 2: Begin enclomiphene during the washout. Starting enclomiphene at 12.5-25 mg daily approximately 10-14 days after the last testosterone enanthate injection (when serum levels have declined enough to partially release hypothalamic suppression) helps stimulate LH and FSH recovery earlier. The SERM provides a pharmacological "push" to the HPG axis before endogenous testosterone has fully recovered, reducing the duration and severity of the symptomatic trough.

Step 3: Monitor labs at 4-week intervals. Check total testosterone, LH, FSH, and estradiol at weeks 4, 8, and 12 post-switch. LH rising above 2-3 mIU/mL signals that the pituitary is responding to enclomiphene. Total testosterone climbing above 400 ng/dL on enclomiphene alone (without residual exogenous contribution) confirms a successful transition.

Step 4: Adjust enclomiphene dose. Most men stabilize on 12.5-25 mg daily. Higher doses (50 mg) rarely provide additional testosterone elevation and increase estradiol disproportionately. The Endocrine Society recommends keeping estradiol monitoring routine on any SERM therapy.

The symptomatic gap is the main clinical challenge. During weeks 2-6 of the switch, men often experience fatigue, low libido, depressed mood, and reduced exercise tolerance. Setting expectations before the switch reduces dropout. Some clinicians prescribe a short course of low-dose hCG (500-1,500 IU two to three times per week for 2-4 weeks) to accelerate Leydig cell reactivation during this window, though evidence for this specific bridge strategy is limited to small case series and clinical consensus rather than randomized trials.

Fertility: The Deciding Factor for Many Men

Fertility preservation is the strongest clinical argument for enclomiphene over testosterone enanthate and the primary reason men switch from enanthate to enclomiphene.

Kim et al. showed that enclomiphene maintained sperm concentrations within normal ranges (above 15 million/mL) in men with secondary hypogonadism throughout the treatment period 1. By contrast, testosterone enanthate reliably suppresses spermatogenesis. A WHO-sponsored contraceptive trial found that 200 mg/week of testosterone enanthate reduced sperm counts to below 1 million/mL in 65% of participants and to azoospermia in 25% within 6 months 6.

Recovery of spermatogenesis after stopping testosterone enanthate is not guaranteed. A meta-analysis published in Fertility and Sterility found that 67% of men recovered sperm counts above 20 million/mL within 6 months of stopping exogenous testosterone, but 10-15% had persistent oligospermia at 12 months. Longer duration of prior TRT use and older age at discontinuation were associated with slower and less complete recovery [5].

Dr. Robert Brannigan, a urologist at Northwestern Medicine, has stated: "We counsel every man starting testosterone therapy that it should be considered a form of male contraception. If future fertility is a priority, alternative approaches like clomiphene or enclomiphene should be first-line."

For men who want both optimized testosterone and preserved fertility, enclomiphene is the clear first choice. Switching to testosterone enanthate should only happen after active fertility goals are completed.

Comparing Efficacy: How Much Testosterone Does Each Drug Produce?

Testosterone enanthate is more predictable in its dosing and peak levels. A dose of 100 mg per week typically produces trough total testosterone levels of 500-700 ng/dL, with peaks reaching 900-1,100 ng/dL at 24-48 hours post-injection 7. The clinician controls the dose directly.

Enclomiphene citrate produces more variable results because it depends on the patient's native testicular reserve. In Kim et al., mean total testosterone rose from baseline values of approximately 230 ng/dL to 450-550 ng/dL on enclomiphene 25 mg daily 1. Some men reached 600-700 ng/dL. Others plateaued at 350-400 ng/dL. The ceiling depends on Leydig cell capacity, which declines with age.

This creates a practical decision point. If a man's symptoms require testosterone levels above 600 ng/dL for relief and enclomiphene can only deliver 450 ng/dL, testosterone enanthate becomes the more effective option for that individual. Symptom response, not a lab number alone, should guide the decision.

The Endocrine Society's 2018 Clinical Practice Guideline recommends maintaining testosterone in the 450-600 ng/dL range for most hypogonadal men, noting that benefits plateau and risks (erythrocytosis, sleep apnea exacerbation) increase at higher levels.

Side Effect Profiles: What Changes When You Switch

Each drug carries distinct adverse effect patterns that shift when patients transition between them.

On enclomiphene: The most reported side effects include headache (8-10% in clinical trials), visual disturbances (blurred vision, floaters; 2-5%), mood irritability, and elevated estradiol. Because enclomiphene raises both testosterone and estradiol (the hypothalamus produces more LH, which stimulates both androgen and estrogen biosynthesis), some men develop tender gynecomastia or water retention. Estradiol levels above 40-50 pg/mL may require dose reduction or, rarely, a low-dose aromatase inhibitor 8.

On testosterone enanthate: The primary concerns are erythrocytosis (hematocrit above 54%, occurring in 5-15% of men), acne, testicular atrophy, HDL cholesterol suppression, and potential worsening of obstructive sleep apnea. The T-Trials also identified a signal of increased coronary artery plaque volume with testosterone therapy, though subsequent larger trials (TRAVERSE, N=5,246) found no increase in major adverse cardiovascular events over a mean follow-up of 33 months 9.

When switching from testosterone enanthate to enclomiphene, expect erythrocytosis to resolve over 2-3 months as hematocrit normalizes. Testicular volume gradually recovers. HDL typically improves. New side effects from enclomiphene (headache, visual changes, estradiol elevation) may appear within the first 4-6 weeks.

When switching from enclomiphene to testosterone enanthate, visual disturbances resolve within days of stopping the SERM. Hematocrit should be monitored starting at 6-8 weeks and every 3-6 months thereafter.

Lab Monitoring Protocol for Either Switch Direction

Consistent lab monitoring prevents complications regardless of which direction the switch goes.

Dr. Mohit Khera, a professor of urology at Baylor College of Medicine, has recommended: "Any transition between hormonal therapies requires a structured lab cadence. I check total and free testosterone, LH, FSH, estradiol, CBC, CMP, and lipids at baseline, then at 6 weeks, 12 weeks, and quarterly for the first year after a switch."

The minimum monitoring schedule:

| Timepoint | Labs | |---|---| | Pre-switch baseline | Total T, free T, LH, FSH, estradiol, SHBG, CBC, PSA, lipids | | 4 weeks post-switch | Total T, LH, FSH (to assess HPG axis status) | | 8 weeks post-switch | Full panel repeat | | 12 weeks post-switch | Full panel, semen analysis (if fertility relevant) | | Quarterly x 1 year | Total T, CBC, estradiol, PSA |

Hematocrit above 54% on testosterone enanthate warrants dose reduction, therapeutic phlebotomy, or both. PSA increases of more than 1.4 ng/mL within 12 months or an absolute value above 4.0 ng/mL should prompt urological evaluation per AUA/Endocrine Society recommendations.

Who Should Not Switch

Not every man is a candidate for switching between these medications.

Men with primary hypogonadism (testicular failure with elevated LH and FSH at baseline) will not respond to enclomiphene. The SERM works by amplifying gonadotropin release, but if the testes cannot respond to LH stimulation, no amount of pituitary drive will raise testosterone. These men require exogenous testosterone.

Men with a history of venous thromboembolism should use caution with enclomiphene, as SERMs carry a class-wide risk of thrombotic events, though the absolute risk with enclomiphene appears lower than with tamoxifen. The FDA prescribing information for clomiphene citrate includes thromboembolism warnings.

Men with polycythemia vera or baseline hematocrit above 50% should avoid testosterone enanthate or use it only with concurrent phlebotomy and close hematologic monitoring.

Testosterone enanthate is contraindicated in men with known or suspected breast or prostate cancer per Endocrine Society guidelines, untreated severe obstructive sleep apnea, or uncontrolled heart failure (NYHA class III-IV).

Cost and Access Considerations

Testosterone enanthate is FDA-approved, available as a generic, and widely covered by insurance. A 10 mL vial of 200 mg/mL typically costs $30-80 without insurance at retail pharmacies.

Enclomiphene citrate remains available primarily through compounding pharmacies and telehealth platforms as of mid-2026. Monthly costs range from $50-150 depending on the source. Insurance coverage is inconsistent. The lack of a branded FDA-approved product for male hypogonadism means prior authorization is rarely available for enclomiphene specifically.

These access differences influence switching decisions in practice. A man stable on compounded enclomiphene whose pharmacy closes or whose costs increase may be forced to transition to testosterone enanthate for practical reasons.